Literature DB >> 10954546

Expression of secreted cytokine and chemokine inhibitors by ectromelia virus.

V P Smith1, A Alcami.   

Abstract

The production of secreted proteins that bind cytokines and block their activity has been well characterized as an immune evasion strategy of the orthopoxviruses vaccinia virus (VV) and cowpox virus (CPV). However, very limited information is available on the expression of similar cytokine inhibitors by ectromelia virus (EV), a virulent natural mouse pathogen that causes mousepox. We have characterized the expression and binding properties of three major secreted immunomodulatory activities in 12 EV strains and isolates. Eleven of the 12 EVs expressed a soluble, secreted 35-kDa viral chemokine binding protein with properties similar to those of homologous proteins from VV and CPV. All of the EVs expressed soluble, secreted receptors that bound to mouse, human, and rat tumor necrosis factor alpha. We also detected the expression of a soluble, secreted interleukin-1beta (IL-1beta) receptor (vIL-1betaR) by all of the EVs. EV differed from VV and CPV in that binding of human (125)I-IL-1beta to the EV vIL-1betaR could not be detected. Nevertheless, the EV vIL-1betaR prevented the interaction of human and mouse IL-1beta with cellular receptors. There are significant differences in amino acid sequence between the EV vIL-1betaR and its VV and CPV homologs which may account for the results of the binding studies. The conservation of these activities in EV suggests evolutionary pressure to maintain them in a natural poxvirus infection. Mousepox represents a useful model for the study of poxvirus pathogenesis and immune evasion. These findings will facilitate future study of the role of EV immunomodulatory factors in the pathogenesis of mousepox.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954546      PMCID: PMC116357          DOI: 10.1128/jvi.74.18.8460-8471.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat.

Authors:  G L Smith; Y S Chan; S T Howard
Journal:  J Gen Virol       Date:  1991-06       Impact factor: 3.891

Review 2.  Vaccinia virus immune evasion.

Authors:  G L Smith; J A Symons; A Khanna; A Vanderplasschen; A Alcamí
Journal:  Immunol Rev       Date:  1997-10       Impact factor: 12.988

3.  The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins.

Authors:  S N Shchelkunov; P F Safronov; A V Totmenin; N A Petrov; O I Ryazankina; V V Gutorov; G J Kotwal
Journal:  Virology       Date:  1998-04-10       Impact factor: 3.616

4.  Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light.

Authors:  K Tsung; J H Yim; W Marti; R M Buller; J A Norton
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Complete nucleotide sequences of two adjacent early vaccinia virus genes located within the inverted terminal repetition.

Authors:  S Venkatesan; A Gershowitz; B Moss
Journal:  J Virol       Date:  1982-11       Impact factor: 5.103

6.  A third distinct tumor necrosis factor receptor of orthopoxviruses.

Authors:  V N Loparev; J M Parsons; J C Knight; J F Panus; C A Ray; R M Buller; D J Pickup; J J Esposito
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

7.  Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene.

Authors:  W Chen; R Drillien; D Spehner; R M Buller
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

8.  Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor.

Authors:  F Q Hu; C A Smith; D J Pickup
Journal:  Virology       Date:  1994-10       Impact factor: 3.616

9.  Potential virulence determinants in terminal regions of variola smallpox virus genome.

Authors:  R F Massung; J J Esposito; L I Liu; J Qi; T R Utterback; J C Knight; L Aubin; T E Yuran; J M Parsons; V N Loparev
Journal:  Nature       Date:  1993 Dec 23-30       Impact factor: 49.962

10.  Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins.

Authors:  K Mossman; C Upton; R M Buller; G McFadden
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

View more
  27 in total

1.  CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses.

Authors:  M Saraiva; A Alcami
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.

Authors:  Meike S Gratz; Yasemin Suezer; Melanie Kremer; Asisa Volz; Monir Majzoub; Kay-Martin Hanschmann; Ulrich Kalinke; Astrid Schwantes; Gerd Sutter
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 3.  Poxvirus immunomodulatory strategies: current perspectives.

Authors:  J B Johnston; Grant McFadden
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

4.  The inflammasome as a target of modulation by DNA viruses.

Authors:  Lisi Amsler; Daniel Malouli; Victor DeFilippis
Journal:  Future Virol       Date:  2013-04-01       Impact factor: 1.831

5.  Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor.

Authors:  B T Seet; R Singh; C Paavola; E K Lau; T M Handel; G McFadden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

6.  Enhanced resistance in STAT6-deficient mice to infection with ectromelia virus.

Authors:  S Mahalingam; G Karupiah; K Takeda; S Akira; K I Matthaei; P S Foster
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

7.  Protective effect of exogenous recombinant mouse interferon-gamma and tumour necrosis factor-alpha on ectromelia virus infection in susceptible BALB/c mice.

Authors:  A V Atrasheuskaya; E K Bukin; T M Fredeking; G M Ignatyev
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

8.  Analysis of an orf virus chemokine-binding protein: Shifting ligand specificities among a family of poxvirus viroceptors.

Authors:  Bruce T Seet; Catherine A McCaughan; Tracy M Handel; Andrew Mercer; Craig Brunetti; Grant McFadden; Stephen B Fleming
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

9.  Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice.

Authors:  Henning Lauterbach; Ronny Kassub; Juliane Pätzold; Jana Körner; Michael Brückel; Admar Verschoor; Paul Chaplin; Mark Suter; Hubertus Hochrein
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

10.  Impact of distinct poxvirus infections on the specificities and functionalities of CD4+ T cell responses.

Authors:  Nicholas A Siciliano; Adam R Hersperger; Aimee M Lacuanan; Ren-Huan Xu; John Sidney; Alessandro Sette; Luis J Sigal; Laurence C Eisenlohr
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.